NovImmune commences NI-0101 Phase I clinical trial in arthritis

NovImmune SA initiated dosing in a Phase I clinical trial of NI-0101, a monoclonal antibody drug candidate targeting toll-like receptor-4 (TLR4).

NI-0101 was discovered and developed by NovImmune, and has broad potential applications. NovImmune has demonstrated efficacy of TLR4 blockade in a range of preclinical models of arthritis, respiratory inflammation, organ injury, as well as other autoimmune and inflammatory conditions. The first-in-human study in healthy volunteers will generate information for pharmacokinetic and pharmacodynamic properties as well as safety and tolerability data.

NovImmune's Chief Medical Officer, Cristina de Min, said, "Data generated during this Phase I program, coupled with the information from pre-clinical experiments in relevant animal models for human diseases, will build a solid foundation to advance NI-0101 into Phase II studies."




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Certain occupations may put workers at increased risk of developing rheumatoid arthritis